KYMR NASDAQ
Credit Risk of going bust: lower than 78% of companies Debt: 0.9% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $0.12 (down 99.9%), Kymera Therapeutics, Inc. would be worth roughly what it owes.
Total debt $82.2M against a stock market value of $9.45B.
Distance to default 9.26 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $41.1M (short-term plus half of long-term), stock volatility 57.7%; Altman Z'' 10.38. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Watertown, MA 02472
US
Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and developing pioneering small molecule therapeutics. These treatments operate by harnessing the body's inherent protein degradation system to selectively eliminate disease-causing proteins. The company's pipeline features several programs, including the IRAK4 program, currently in Phase I clinical trials, which targets various immunology-inflammation disorders such as hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, generalized pustular psoriasis, and rheumatoid arthritis. Additionally, Kymera is advancing its IRAKIMiD program, designed to address MYD88-mutated diffuse large B cell lymphoma. Other key programs include the STAT3 program, focused on hematological malignancies, solid tumors, autoimmune diseases, and fibrosis, as well as the MDM2 program, which is also aimed at hematological malignancies and solid tumors. The company was founded in 2015 and maintains its headquarters in Watertown, Massachusetts.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Mainolfi Nello | S-Sale | 3,525 | $111.44 | 2026-10-01 |
| Mainolfi Nello | S-Sale | 5,506 | $112.42 | 2026-10-01 |
| Mainolfi Nello | S-Sale | 4,876 | $113.24 | 2026-10-01 |
| Mainolfi Nello | S-Sale | 7,601 | $114.43 | 2026-10-01 |
| Mainolfi Nello | S-Sale | 8,230 | $115.40 | 2026-10-01 |